Acute Hepatic Porphyria

Screen patients with otherwise unexplained recurrent severe abdominal pain after an initial evaluation, particularly women aged 15 to 50 years. Escalate suspicion when attacks include nausea, confusion, hyponatremia, tachycardia, hypertension, or motor-predominant neuropathy; these features occur across acute intermittent porphyria (AIP), hereditary coproporphyria (HCP), and variegate porphyria (VP). PubMed+2PubMedAGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert ReviewScienceDirectAcute hepatic porphyrias: Recommendations for diagnosis and management with real-world examplesPubMedDiagnosis and management of porphyria - PMC

Do not use nonspecific abdominal pain, psychiatric symptoms, or a family history alone to diagnose AHP. Acute attacks can mimic common gastrointestinal, neurologic, and psychiatric conditions, and the diagnostic pathway begins with biochemical evidence of excess heme-pathway intermediates. ScienceDirect+2ScienceDirectAcute hepatic porphyrias: Recommendations for diagnosis and management with real-world examplesPubMedAcute hepatic porphyrias: Recommendations for evaluation and long-term management - PubMedPubMedAGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert Review

Cutaneous photosensitivity or blistering shifts the subtype differential toward VP or HCP: skin lesions accompany attacks in approximately one-half of VP and one-third of HCP cases, whereas AIP is principally neurovisceral. This distinction should prompt specialty porphyrin characterization after biochemical confirmation rather than delay initial urine precursor testing. PubMed+1PubMedDiagnosis and management of porphyria - PMCPubMedAcute hepatic porphyria and anaesthesia: a practical approach to the prevention and management of acute neurovisceral attacks

For initial evaluation, measure urinary porphobilinogen (PBG), δ-aminolevulinic acid (ALA), total porphyrins, and creatinine in a random urine specimen. Creatinine permits interpretation despite variable urine concentration, and this panel is the AGA-recommended initial diagnostic test set for AHP. PubMed+1PubMedAGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert ReviewScienceDirectAcute hepatic porphyrias: Recommendations for diagnosis and management with real-world examples

A positive biochemical screen should be followed by molecular genetic testing to confirm AHP and identify the pathogenic variant. Genetic testing is most useful after biochemical evidence of disease activity and then supports counseling and cascade testing of relatives. PubMed+2PubMedAGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert ReviewPubMedAcute hepatic porphyrias: Recommendations for diagnosis and management with real-world examples. - AbstractPubMedAcute Intermittent Porphyria - GeneReviews® - NCBI Bookshelf - NIH

When a newly confirmed patient has no prior family diagnosis, use light-protected plasma and fecal porphyrin analysis in a specialist laboratory to distinguish AIP, VP, and HCP. Plasma fluorescence emission and fecal porphyrin-excretion patterns provide subtype discrimination; urinary precursor elevation alone establishes AHP activity but may not define the specific subtype. PubMedPubMedAcute hepatic porphyria and anaesthesia: a practical approach to the prevention and management of acute neurovisceral attacks

A urine dipstick urobilinogen result is not a replacement for PBG and ALA measurement. In one abdominal-pain study, a urinary urobilinogen-to-serum total bilirubin ratio above 3.22 identified AIP, HCP, and VP with reported 100% sensitivity and specificity; use it only as a prompt for definitive urinary PBG, ALA, and, when indicated, genetic testing. NatureNatureA high urinary urobilinogen/serum total bilirubin ratio indicates acute hepatic porphyria in patients with abdominal pain | Scientific Reports

Hospitalize patients with severe attacks, inability to maintain oral intake, significant autonomic instability, hyponatremia, progressive neuropathy, or concern for respiratory weakness. For attacks severe enough to require admission, administer intravenous hemin daily, preferably through a high-flow central vein. Treatment does not require determination of the exact AHP subtype once an acute porphyria diagnosis is biochemically established. PubMed+1PubMedAGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert ReviewPubMedAcute Hepatic Porphyria - StatPearls - NCBI Bookshelf

Manage the attack in parallel: provide analgesia, antiemetics, and directed treatment of systemic hypertension, tachycardia, hyponatremia, and hypomagnesemia. Use only medications considered safe for porphyria and discontinue identifiable porphyrinogenic drugs. PubMed+1PubMedAGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert ReviewPubMedDiagnosis and management of porphyria - PMC

For mild acute neurovisceral attacks, use high carbohydrate intake, preferably orally. If intravenous carbohydrate is required for up to 48 hours, GeneReviews describes glucose-containing fluid with at least 5% dextrose; 10% glucose with sodium 40 mmol and potassium 20 mmol in 1,000 mL over 12 hours is commonly recommended. Avoid hypotonic dextrose-in-water solutions because they can worsen hyponatremia. PubMedPubMedAcute Intermittent Porphyria - GeneReviews® - NCBI Bookshelf - NIH

Hemin infusion technique affects vascular risk. Reconstituting hematin in 20% human serum albumin and using a large peripheral vein or central catheter can reduce phlebitis; use an in-line filter, replace a peripheral cannula after each administration, and flush venous catheters with a total 200 mL saline bolus. PubMedPubMedAcute Intermittent Porphyria - GeneReviews® - NCBI Bookshelf - NIH

Define recurrent acute attacks as 4 or more attacks annually; distinguish these patients from those with sporadic attacks occurring fewer than 4 times per year. Recurrent disease warrants close follow-up because attack prevention, treatment modification, and complication surveillance are more likely to be necessary. PubMedPubMedAcute hepatic porphyrias: Recommendations for evaluation and long-term management - PubMed

At every recurrence, perform a medication review that includes hormonal contraception, assess alcohol exposure, investigate infection or other intercurrent disease, and obtain dietary and nutritional history. Avoid identifiable precipitants, including alcohol and porphyrinogenic medications; reduced caloric intake, prolonged fasting, dehydration, and certain hormonal exposures are actionable trigger domains. PubMed+2PubMedAGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert ReviewPubMedAcute Hepatic Porphyrias: Current Diagnosis & ManagementPubMedAcute hepatic porphyria and anaesthesia: a practical approach to the prevention and management of acute neurovisceral attacks

For recurrent acute attacks, consider outpatient prophylactic heme therapy or givosiran. Givosiran is an siRNA therapy directed against hepatic ALAS1 and has demonstrated reduction in acute attacks in a phase III trial; selection between prophylactic heme and givosiran should occur with porphyria expertise because ongoing attack burden and treatment response drive modification. PubMed+2PubMedAGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert ReviewScienceDirectAcute hepatic porphyrias: Recommendations for diagnosis and management with real-world examplesPubMedHereditary Coproporphyria - PubMed

Refer every patient who has experienced an acute attack to a porphyria specialist for longitudinal care. Annual assessment should include biochemical testing and monitoring for long-term complications, with follow-up frequency intensified for recurrent attacks and patients receiving treatment changes. PubMed+1PubMedAcute hepatic porphyrias: Recommendations for evaluation and long-term management - PubMedPubMedAcute hepatic porphyria and anaesthesia: a practical approach to the prevention and management of acute neurovisceral attacks

A known AHP diagnosis is not a contraindication to anesthesia. Before elective procedures, avoid porphyrinogenic medicines, prolonged fasting, dehydration, and inadequate analgesia; coordinate the medication plan with an anesthesia team and a current porphyria drug-safety resource. ScienceDirect+1ScienceDirectAcute hepatic porphyria and anaesthesia: a practical approach to ...PubMedAcute hepatic porphyria and anaesthesia: a practical approach to the prevention and management of acute neurovisceral attacks

After positive biochemical testing, genetic confirmation should be used to identify the pathogenic variant and facilitate cascade testing. Family testing is clinically useful because many carriers remain asymptomatic, while identification permits anticipatory counseling regarding medications, alcohol, fasting, and other triggers. PubMed+2PubMedAGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert ReviewPubMedAcute hepatic porphyrias: Recommendations for diagnosis and management with real-world examples. - AbstractPubMedAcute hepatic porphyria and anaesthesia: a practical approach to the prevention and management of acute neurovisceral attacks